SRNE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 27, 2020 in the Class Action Filed on Behalf of Sorrento Therapeutics, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - July 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) alleging that the Company violated federal securities laws.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7092/60338_932901_logo.jpg

Class Period: May 15, 2020 and May 22, 2020
Lead Plaintiff Deadline: July 27, 2020

Learn more about your recoverable losses in DNK:
http://www.kleinstocklaw.com/pslra-1/sorrento-therapeutics-inc-loss-submission-form?id=8116&from=5

The filed complaint alleges that Sorrento Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders have until July 27, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the SRNE lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60338

info